Complete Story


Free CME on off-label use of atypical antipsychotics

A FREE CME Program

Prescribing of atypical antipsychotics has expanded beyond the FDA approved indications, but their effectiveness, benefits, and adverse effects in off-label uses are not well understood. How do atypical antipsychotic medications compare with other drugs for "off-label" indications?  This program can help!

The Agency for Healthcare Research and Quality (AHRQ) has awarded the APA a grant (#5R18HS021944) to create and offer physicians a FREE CME program to educate them about evidence for effectiveness of atypical (second generation) antipsychotics, reviewed in the 2011 AHRQ Report. The goal of the program is to help physicians make informed treatment decisions when using these medications "off label". This interactive CME program begins with a Self-Assessment test and in the months that follow a series of multimedia clinical modules will be available for CME credit.  The self-assessment test is available at

According to the 2011 AHRQ review, which atypical has the most evidence for effectiveness in managing dementia-related agitation?

A.     Aripiprazole

B.     Quetiapine

C.     Risperidone

D.     Ziprasidone

Find the answer by taking the self-assessment!


The APA is accredited by the ACCME to provide continuing medical education for physicians. The APA designates this Self-Assessment for a maximum of 5 AMA PRA Category 1 CreditsTM. Physicians should only claim credit commensurate with the extent of their participation in the activity. 

This activity is a continuation of APA'S FOCUS program of lifelong learning and is approved by ABPN as a MOC Part 2, Self-Assessment activity.


For more information click here:


Printer-Friendly Version